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Conclusions: All the treatment plans could meet the clinical therapy 
needs. The dose measurements also showed good agreement with 
computed doses. RapidArc technique can treat patients with advanced 
NPC effectively, with good target coverage and sparing of critical 
structures. RA has a slightly dosimetric superiority than RA-FFF. 
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Purpose/Objective: To quantify positional variation of the anal canal 
and inguinal lymph nodes and derive the required CTV-to-PTV 
margins. 
Materials and Methods: Ten anal cancer patients were included in 
this retrospective study, 5 male and 5 female. All patients were 
treated prone using a feet cushion to maintain a stable positioning of 
the legs over the course of treatment. In male patients, the penis and 
testicles were lifted using a scrotum holder to avoid contact between 
the target volume and these healthy tissues. Cone Beam CT scans 
were made daily prior to treatment for the first 3 fractions, and 
weekly thereafter, in the context of an offline shrinking action level 
(SAL) setup correction protocol. A total of 95 CBCT were made and 
registered to the planning CT scan.  
Setup errors were measured by evaluating the chamfer match of the 
pelvic bones. The 'organ motion' of the inguinal lymph nodes and the 
anal canal relative to the pelvic bony anatomy were measured by grey 
value registration of these structures (see figure). CTV-to-PTV margins 
were calculated based on an offline correction protocol and assuming 
a 4 mm delineation uncertainty according to: M=2.5Σ+0.7σ. 
 
  
Figure. Coronal view of the four region of interests used for 
registration; a) pelvic bones, b) inguinal lymph nodes right, c) inguinal 
lymph nodes left and d) anal tumor. 
Results: Group mean (GM), systematic error (Σ) and random error (σ) 
of the 'organ motion' of the inguinal lymph nodes and the anal canal 
are given in the table. Required CTV-to-PTV margins assuming an 
offline SAL protocol with the pelvic bones as surrogate for the 
treatment volume are also shown in the table. Margins for a pelvic 
bone online correction protocol were identical as the contribution of 
the setup error was negligible. 
 
  
Table. The Group Mean (GM), systematic error (Σ) and random error 
(σ) of the 'organ motion' of the inguinal lymph nodes right (r) and left 
(l) and the anal canal (CTV) and the margins required for an offline 
registration protocol.  
Conclusions: This study indicates that standard clinical CTV-to-PTV 
margins of 1cm and/or the registration protocol should be adjusted to 
deliver 95% of the prescribed dose to the CTV/lymph nodes for 90% of 
the patients. Adaptive radiotherapy enables compensation for the 
(differential) systematic errors of both the CTV and lymph nodes, 
allowing margins reduction.  
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SP-0353   
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What more natural than a stress response that would vary among 
individuals? The individual factor has been pointed out in numerous 
medical research areas. The idea that each individual shows a specific 
response to radiation, like face to any stress, is well-accepted by 
public, but neither taken into account into radioprotection 
recommendations nor in a systematic process of prediction in 
radiotherapy or chemotherapy. However, to date, there is much 
evidence that about 5-15% individuals are radiosensitive i.e 
susceptible to adverse tissue reactions and/or radiation-induced 
cancer. Besides, the confusion between these last two notions due to 
toxicity and cancer proneness, respectively has not facilitated the 
prediction of patients at risk. Indeed, the long quest of "the" 
predictive assay still meet technical artefacts, cell types 
specificities, lacks in the understanding of the molecular and cellular 
responses and fashion effects. The major approaches to predict 
radiosensitivity are functional assays (notably DNA repair and signaling 
pathways), gene expression assay and detection of polymorphisms 
(SNP). Considering that there is a continuum in the radio-responses 
(i.e. radiosensitivity is not an all-or-none phenomenon), it is hard to 
imaging one SNP responsible for all the radiosensitivities and one SNP 
for each radiosensitivity, inasmuch as SNP may also depend on the cell 
and tissue type. Considering that few genes show a dose-dependent 
response with the same rate as cell death or mutagenesis, it is also 
difficult to identify "the" gene expression that would predict all the 
radiosensitivity. Conversely, results of nearly 40 years of research, 
functionnal assays of repair or signalling pathways of DNA damage, 
especially DNA double-strand breaks (DSB) are promising yet because 
some quantitative correlations has been demonstrated between 
clinical, cellular and molecular features, whatever the dose.  
Unfortunately, the methodology and the endpoints that would predict 
radiosensitivity are still to be determined. Here, we propose a 
classification of radiosensitivity based on the kinetics of the radiation-
induced nucleo-shuttling of the ATM protein. 
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